Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumabRita De Sanctis, Armando Santoro, Arianna Marinello et al.|The Breast|2021Cited by 10
Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancerRita De Sanctis, Armando Santoro, Federica D’Antonio et al.|Annals of Oncology|2018Cited by 1